Loyola University Chicago is a private Jesuit research university in Chicago, Illinois. Founded in 1870 by the Society of Jesus, Loyola is one of the largest Catholic universities in the United States. Its namesake is Saint Ignatius of Loyola.

During the past decade, Loyola University Chicago conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 8 clinical trials were completed, i.e. on average, 53.3% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 5 clinical trials were completed. i.e. 83.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Loyola University Chicago" #1 sponsor was "Loyola University Chicago" with 2 trials, followed by "United Therapeutics" with 2 trials sponsored, "University of Minnesota" with 2 trials sponsored, "Abbott Medical Devices" with 1 trials sponsored and "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Loyola University Chicago" #1 collaborator was "University of Alabama at Birmingham" with 3 trials as a collaborator, "Loyola University Chicago" with 2 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator, "United States Department of Defense" with 2 trials as a collaborator and "University of California, San Diego" with 2 trials as a collaborator. Other collaborators include 20 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "Loyola University Chicago" are "Idiopathic Pulmonary Fibrosis" (2 trials), "Lower Urinary Tract Symptoms" (2 trials), "Pulmonary Arterial Hypertension" (2 trials), "Advanced Renal Cell Carcinoma" (1 trials) and "Arthritis, Rheumatoid" (1 trials). Many other conditions were trialed in "Loyola University Chicago" in a lesser frequency.

Most popular intervention types in "Loyola University Chicago" are "Drug" (13 trials), "Device" (7 trials), "Behavioral" (3 trials), "Biological" (3 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "ACE-I (lisinopril) or ARB (losartan)" (1 trials), "Antimicrobial therapy: Co-trimoxazole or Doxycycline" (1 trials), "Artemis + Medical Management" (1 trials) and "Aspirin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Loyola University Chicago" are 23 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Loyola University Chicago". undefined are not yet recruiting, 6 are recruiting, 5 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 10 completed trials in Loyola University Chicago, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Loyola University Chicago, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 9 trials that are defined as “Not Applicable".

Loyola University Chicago has several departments that took part in Clinical trials: "Loyola University Chicago Health Sciences Division" - 2 trials